Drug intelligence / Profile preview

PL-3100

Development stage: Phase 2
Lead developer: PLx Pharma
Modality: Small Molecules
Administration: Oral

Overview

PL-3100 is an oral agent that was being developed by PLx Pharma for the treatment of gastroduodenal ulcerations and erosion. The drug's specific mechanism of action is not detailed in the available sources, but it was intended to address gastrointestinal mucosal injury, likely as a reformulation or novel delivery approach to improve safety or efficacy in this indication[1].

Other names: Naproxen-PC

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on PL-3100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-3100.

Explore the full profile